The IL1B Knockout 786-O Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population targeting the human IL1B gene in the 786-O renal cell carcinoma cell line. This loss-of-function model is generated through CRISPR/Cas9-mediated gene disruption, producing a heterogeneous pool of cells deficient in interleukin-1?? (IL-1??) expression. The polyclonal format preserves population diversity, making it suitable for robust functional assays. Researchers can employ these cells to dissect IL-1??-dependent signaling without endogenous cytokine interference.
The 786-O host cell line is a human clear cell renal cell carcinoma (ccRCC) epithelial model derived from a primary renal adenocarcinoma. It exhibits VHL tumor suppressor deficiency, leading to constitutive HIF stabilization and hypoxic signaling. As a proximal tubule epithelial line, it recapitulates key aspects of ccRCC biology, including interactions between oncogenic drivers and inflammatory mediators.
IL1B encodes interleukin-1??, a pro-inflammatory cytokine upregulated by TNF-alpha, LPS, NF-kB, and HIF-1??. Secreted IL-1?? binds the IL1R1/IL1RAP receptor complex, recruiting MyD88 to activate IRAK4 and IRAK1, which then signal through TRAF6. This triggers the IKK complex to release NF-kB, driving transcription of inflammatory mediators such as IL-6, CXCL8/IL-8, ICAM1, and PTGS2/COX-2, while simultaneously activating JNK and p38 MAPK pathways. The resulting gene expression program promotes inflammation and tissue remodeling. In 786-O cells, VHL deficiency and HIF-1?? accumulation may amplify IL-1?? responses.
Disruption of IL1B eliminates autocrine and paracrine IL-1?? signaling, reducing NF-kB and MAPK target gene expression. This knockout model allows specific investigation of IL-1?¡?s role in ccRCC-associated inflammation, migration, and invasion. It also enables exploration of crosstalk between VHL-dependent hypoxic pathways and IL-1?? signaling, potentially uncovering therapeutic targets. Thus, these cells serve as a powerful tool for studying inflammation-driven renal cancer progression.
Typical applications include Western blotting and ELISA for IL-1?? confirmation, RT-qPCR for transcriptional effects, NF-kB reporter assays, phospho-p65 immunofluorescence, and cell migration/invasion studies. They are suitable for drug sensitivity testing with IL-1R antagonists and inflammasome research. Additionally, they facilitate cytokine crosstalk analysis and tumor microenvironment studies. For further information, contact Ascent Research.
